UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

usinington, D.C. 200

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of <u>August 2014</u>

File No. <u>000-54598</u>

Stellar Biotechnologies Inc.

(Name of Registrant)

332 E. Scott Street, Port Hueneme, CA 93041

(Address of Principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

FORM 20-F x FORM 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

SIGNATURE

Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

<u>Stellar Biotechnologies, Inc.</u> (Registrant)

Dated: 8/28/14

By: <u>/s/ Kathi Niffenegger</u> Kathi Niffenegger Chief Financial Officer

Exhibits:

99.1 Notice of Change of Financial Year-End

NOTICE OF CHANGE OF FINANCIAL YEAR-END

August 28, 2014

British Columbia Securities Commission Alberta Securities Commission

Dear Sirs

Re: Stellar Biotechnologies, Inc. (the "Company") Notice Pursuant to Section 4.8 of National Instrument 51-102

Pursuant to Section 4.8 of National Instrument 51-102 *Continuous Disclosure Obligations*, the Company wishes to advise that it is changing its financial yearend from August 31 to September 30.

Reason for the Change

Fiscal year and quarterly filings to coincide with calendar quarters.

Relevant Dates for Financial Reporting Periods

The old financial year-end of the Company was August 31.

The new financial year-end of the Company will be September 30.

The transition year of the Company will be the one month ended September 30, 2014.

The length, ending dates and filing deadlines of the periods, including the comparative periods, of the annual financial statements to be filed for the Company's transition year and its new financial year are as follows:

Transition Year	Comparative Annual	Filing Deadline for	New Financial	Comparative Annual	Canadian Filing	US Filing Deadline
	Financial Statements	Annual Statements	Year	Financial Statements	Deadline for	for Annual
	to Transition Year	for Transition Year		to New Financial Year	Annual Financial	Financial
					Statements for	Statements for
					New Financial	New Financial
					Year	Year
One month ended	Filed with New	Filed with New	Twelve months	One month ended	January 28, 2016	December 14, 2015
September 30, 2014	Financial Year	Financial Year	ended September	September 30, 2014 and		
			30, 2015	twelve months ended		
				August 31, 2014		

The length, ending dates and filing deadlines of the periods, including the comparative periods, of the interim financial statements to be filed for the Company's transition year and its new financial year are as follows:

Interim Periods for Transition Year	Comparative Interim Periods to Interim Periods in Transition Year	Filing Deadline for Interim Financial Statements of Transition Year	Interim Periods for New Financial Year	Comparative Interim Periods in New Financial Year	Canadian Filing Deadline for Interim Financial Statements of New Financial Year	US Filing Deadline for Interim Financial Statements of New Financial Year
N/A	N/A	N/A	Three months ended December 31, 2014	Three months ended December 31, 2013	March 2, 2015	February 9, 2015
			Three and six months ended March 31, 2015	Three and six months ended March 31, 2014	June 1, 2015	May 10, 2015
			Three and nine months ended June 30, 2015	Three and nine months ended June 30, 2014	August 31, 2015	August 9, 2015

DATED at Port Hueneme, California, this 28th date of August, 2014.

STELLAR BIOTECHNOLOGIES, INC.

Per: /s/ Kathi Niffenegger

Kathi Niffenegger Chief Financial Officer